研究摘要

世德主要的研究摘要和出版物

Cytopeutics® 与当地和国际医疗机构、学术界和研究机构合作，在国际同行评审期刊和国际会议上发表了许多研究成果。

Heart Disease-01
查看详情
Heart Disease-02
查看详情
Heart Disease-03
查看详情
Lung Disease
查看详情
Chronic Kidney Disease
查看详情
Acute Stroke
查看详情
Brain & Spinal Cord
查看详情
Diabetes-01
查看详情
Diabetes-02
查看详情
CLV 100 Immunomodulation
查看详情
Autoimmune Disease
查看详情
GVHD
查看详情
EMIT
查看详情
Knee Osteoarthritis-01
查看详情
Knee Osteoarthritis-02
查看详情
Liver Disease
查看详情
Eye Disease-01
查看详情
Eye Disease-02
查看详情
Critical Limb Ischemia
查看详情
了解更多关于世德的消息：
欢迎联络我们！

Send Us a Message

Logo

Cytopeutics® is the multi-award winning and trusted provider of mesenchymal stem cells (MSC) for clinical trials and treatment in the Asia-Pacific region.

Instagram
Sitemap
About Us
Get In Touch
  • Phone
  • Mail
  • ENG / CN
  • ENG / BM
× Send

Copyright © Cytopeutics Sdn. Bhd. (Company No:200701018117 (776128-H)). Website managed by Exabytes. All rights reserved.

Synergistic effects of intracoronary infusion of autologous bone marrow-derived mesenchymal stem cells and revascularization procedure on improvement of cardiac function in patients with sever ischemic cardiomyopathy.
Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll/lll randomized controlled trial.
Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy.
Improved cells survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension.
Mesenchymal stromal cells (Cyto-MSC) are well-tolerated and associated with renal function improvement in patients with chronic kidney disease: An observation retrospective study.
BM-MSC accelerates acute stroke recovery in a randomized placebo- controlled clinical phase ll/lll study.
Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro.
Allogenic cord-derived MSC infusion is safe and improves metabolic functions of uncontrolled diabetes patients.
Allogenic Wharton’s jelly mesenchymal stromal cells intravenous infusion increase serum insulin like growth factor 1 and dehydroepiandrosterone in healthy volunteers.
Dose-dependent immunomodulatory effect of intravenous allogenic umbilical cord-derived mesenchymal stromal cells (Cytopeutics CLV-100) infusion in healthy volunteers.
Autologous bone marrow mesenchymal stromal cells can treat arthritic joints of rheumatoid arthritis patients: Reports of two patients.
Cytopeutics® umbilical cord mesenchymal stromal cells (CYTO-MSC) for patients with grade ll-lv acute graft-versus-host disease: A phase l/ll clinical study-protocol overview.
A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from criticallyill cancer patients without the need for apheresis or peripheral mobilization.
Arthroscopic evidence of cartilage regeneration in severe knee cartilage defects and osteoarthritis following treatment with allogenic umbilical cord-derived mesenchymal stromal cells (Chondrocell- Ex).
Intra articular injection of autologous bone-marrow-derived mesenchymal stromal cells in patients with moderate to severe osteoarthritis.
Umbilical cord-derived mesenchymal stem cell infusion improved liver function in liver cirrhosis and is associated with viral load reduction.
Autologous cultivated oral mucosal epithelial cells transplantation (COMET) with amniotic membrane-based sheets for severe ocular chemical injury.
Safety and efficacy of human Wharton’s jelly-derived mesenchymal stem cells therapy for retinal degeneration.
Combination BM-MSC with BM-MNC is better than BM-MNC alone in resolution of large ischemic ulcers: A phase ll/lll clinical randomized study.